Xinjing Zhiyuan Raises Over RMB 200 Million in Series B Financing to Advance TCR-T Therapies for Solid Tumors
Neowise
Solid Tumor TCR-T Cell Therapy Drug Developer
1Month26Day, Focused on Solid TumorsTCR-TNeowise Biotechnology Announces Completion of Over2100 Million YuanBThis round of financing was led by Apricot Capital and a well-known industry fund, with follow-up investments from Delian Capital, Oriza Holdings, and Suzhou Angel Mother Fund. Existing shareholders Tonggao Capital and GEM continued to strongly support the company.
Neowise Biotechnology was founded in2020Year, headquartered in Suzhou, focusing on solid tumorsTCR-TDevelopment of Immunocyte Therapeutic Drugs: The company independently developed high-throughput, high-sensitivity target antigens.-NaturalTCRDiscovery Platform, through iterative feedback combining computational and experimental validation, efficiently screens for natural high-affinity specific recognition of tumor antigens.TCRSequence, EstablishedGlobal Leader, Tumor Target Antigens Validated by Experiments-NaturalTCRPaired Database (CAST®）Currently, multiple pipelines have advanced to the clinical trial stage, and positive efficacy and good safety have been observed in clinical trials targeting various solid tumors.
Among them,NW-101CIndependently developed by the company,TargetedPRAMETheTCR-TCell therapy candidate drug, isThe first product in China to enter the clinical stage for this target., has achieved positive efficacy in a variety of end-stage solid tumors, and is currently undergoingIThe registered clinical studies include indications such as ovarian cancer, malignant melanoma, esophageal squamous cell carcinoma, squamous cell carcinoma of the lung, soft tissue sarcoma, and triple-negative breast cancer.
NW-301VIndependently developed by the company,TargetedKRAS G12VMutationTheTCR-TCell therapy candidate drug, the preliminary clinical research results of which have been2025 ESMOSelected Oral Report at the Annual Meeting(proffered paper presentation)in the form of publication, this isFirst Systematic Disclosure on a Global ScaleTargeting this targetTCR-TClinical drug data. As of2025Year7Monthly Entry Group14Example can be evaluated latePatients with advanced colorectal cancer and pancreatic cancer, etc.,NW-301VDemonstrated good safety and efficacy. In terms of safety, no dose-limiting toxicity or serious adverse reactions were observed. In terms of efficacy, patients treated with medium and high dose groups showed positive results.10Objective Response Rate (ORR) in the Example Subjects (ORR) Reach50%, Disease Control Rate (DCR) Reach100%。
It is reported that the proceeds from this round of financing will be mainly used for the clinical research of Neowise Biotechnology's core pipelines and the advancement of multiple pre-clinical pipelines, accelerating the process of the company’s innovative drugs moving towards clinical, commercialization, and internationalization.
"Frontier π" Column
PharmaCube Pro